Abstract
Cyclooxyganase-2 (COX-2), a rate-limiting enzyme in the prostaglandin synthesis pathway, is overexpressed in many cancers and contributes to cancer progression through tumor cell-autonomous and paracrine effects. Regular use of non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors (COXIBs) reduces the risk of cancer development and progression, in particular of the colon. The COXIB celecoxib is approved for adjunct therapy in patients with Familial adenomatous polyposis at high risk for colorectal cancer (CRC) formation. Long-term use of COXIBs, however, is associated with potentially severe cardiovascular complications, which hampers their broader use as preventive anticancer agents. In an effort to better understand the tumor-suppressive mechanisms of COXIBs, we identified MAGUK with Inverted domain structure-1 (MAGI1), a scaffolding protein implicated in the stabilization of adherens junctions, as a gene upregulated by COXIB in CRC cells and acting as tumor suppressor. Overexpression of MAGI1 in CRC cell lines SW480 and HCT116 induced an epithelial-like morphology; stabilized E-cadherin and β-catenin localization at cell–cell junctions; enhanced actin stress fiber and focal adhesion formation; increased cell adhesion to matrix proteins and suppressed Wnt signaling, anchorage-independent growth, migration and invasion in vitro. Conversely, MAGI1 silencing decreased E-cadherin and β-catenin localization at cell–cell junctions; disrupted actin stress fiber and focal adhesion formation; and enhanced Wnt signaling, anchorage-independent growth, migration and invasion in vitro. MAGI1 overexpression suppressed SW480 and HCT116 subcutaneous primary tumor growth, attenuated primary tumor growth and spontaneous lung metastasis in an orthotopic model of CRC, and decreased the number and size of metastatic nodules in an experimental model of lung metastasis. Collectively, these results identify MAG1 as a COXIB-induced inhibitor of the Wnt/β-catenin signaling pathway, with tumor-suppressive and anti-metastatic activity in experimental colon cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR et al. (2009). Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 16: 712–723.
Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728–734.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila, Pa) 2: 310–321.
Bieler G, Hasmim M, Monnier Y, Imaizumi N, Ameyar M, Bamat J et al. (2007). Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappaB activation and endothelial cell survival. Oncogene 26: 5722–5732.
Buchanan FG, DuBois RN . (2006). Connecting COX-2 and Wnt in cancer. Cancer Cell 9: 6–8.
Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, Morello V et al. (2010). Integrins and signal transduction. Adv Exp Med Biol 674: 43–54.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS . (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs–axin–beta-catenin signaling axis. Science 310: 1504–1510.
Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, Gomez del Pulgar MT et al. (2007). Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170: 1077–1085.
Cha YI, DuBois RN . (2007). NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58: 239–252.
Chastre E, Abdessamad M, Kruglov A, Bruyneel E, Bracke M, Di Gioia Y et al. (2009). TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J 23: 916–928.
Clevers H . (2006). Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.
Cuzick JF BJ, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M . (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501–507.
Dobrosotskaya I, Guy RK, James GL . (1997). MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein–protein interaction domains. J Biol Chem 272: 31589–31597.
Dobrosotskaya IY . (2001). Identification of mNET1 as a candidate ligand for the first PDZ domain of MAGI-1. Biochem Biophys Res Commun 283: 969–975.
Dobrosotskaya IY, James GL . (2000). MAGI-1 interacts with beta-catenin and is associated with cell–cell adhesion structures. Biochem Biophys Res Commun 270: 903–909.
Dormond O, Foletti A, Paroz C, Ruegg C . (2001). NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7: 1041–1047.
Fodde R, Brabletz T . (2007). Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19: 150–158.
Futaki N, Takahashi S, Kitagawa T, Yamakawa Y, Tanaka M, Higuchi S . (1997). Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm Res 46: 496–502.
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C et al. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765–770.
Gupta RA DR . (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11–21.
Gupta RA, Dubois RN . (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11–21.
Hirao K, Hata Y, Ide N, Takeuchi M, Irie M, Yao I et al. (1998). A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins. J Biol Chem 273: 21105–21110.
Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM . (1999). Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res 59: 1572–1577.
Ide N, Hata Y, Nishioka H, Hirao K, Yao I, Deguchi M et al. (1999). Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells. Oncogene 18: 7810–7815.
Ilyas M, Straub J, Tomlinson IP, Bodmer WF . (1999). Genetic pathways in colorectal and other cancers. Eur J Cancer 35: 1986–2002.
Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA . (2000). The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040–5044.
Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ et al. (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418–1423.
Kawajiri A, Itoh N, Fukata M, Nakagawa M, Yamaga M, Iwamatsu A et al. (2000). Identification of a novel beta-catenin-interacting protein. Biochem Biophys Res Commun 273: 712–717.
Koch A, Weber N, Waha A, Hartmann W, Denkhaus D, Behrens J et al. (2004). Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J Pathol 204: 546–554.
Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E . (2005). Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J 19: 115–117.
Laura RP, Ross S, Koeppen H, Lasky LA . (2002). MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp Cell Res 275: 155–170.
Meade EA, Smith WL, DeWitt DL . (1993). Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610–6614.
Mino A, Ohtsuka T, Inoue E, Takai Y . (2000). Membrane-associated guanylate kinase with inverted orientation (MAGI)-1/brain angiogenesis inhibitor 1-associated protein (BAP1) as a scaffolding molecule for Rap small G protein GDP/GTP exchange protein at tight junctions. Genes Cells 5: 1009–1016.
Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC et al. (2008). CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323–7331.
Noda M, Tatsumi Y, Tomizawa M, Takama T, Mitsufuji S, Sugihara H et al. (2002). Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin–catenin complexes in gastrointestinal cell lines. J Gastroenterol 37: 896–904.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS . (2002). Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289–293.
Shao J, Jung C, Liu C, Sheng H . (2005). Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280: 26565–26572.
Shao J, Lee SB, Guo H, Evers BM, Sheng H . (2003). Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63: 5218–5223.
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S et al. (2001). Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048–1051.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952.
Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC et al. (2008). Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75: 668–676.
Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV . (2006). Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCM in mice. Cancer Res 66: 7370–7377.
Taylor J, Abramova N, Charlton J, Adler PN . (1998). Van Gogh: a new Drosophila tissue polarity gene. Genetics 150: 199–210.
Tsujii M, DuBois RN . (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493–501.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716.
Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP et al. (2008). Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 68: 1213–1220.
Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R . (1999). Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18: 305–314.
Wang D, Dubois RN . (2006). Prostaglandins and cancer. Gut 55: 115–122.
Wang D, Mann JR, DuBois RN . (2004). WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle 3: 1512–1515.
Wolff T, Rubin GM . (1998). Strabismus, a novel gene that regulates tissue polarity and cell fate decisions in Drosophila. Development 125: 1149–1159.
Yao R, Natsume Y, Noda T . (2004). MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap. Oncogene 23: 6023–6030.
Zaric J, Ruegg C . (2005). Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem 280: 1077–1085.
Acknowledgements
We thank Drs M Aguet, Y Hata, L Naldini, A Follenzi and R Iggo for sharing reagents; F Derouet and D Uldry for invaluable technical assistance; N Rives for proof reading the paper and Pfizer for providing celecoxib. This work was supported by grants from the Medic Foundation, the National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation), the European Union under the auspices of the FP7 collaborative project TuMIC (contract number HEALTH-F2-2008-201662) and by the Swiss Cancer League (OCS 020020-02-2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Zaric, J., Joseph, JM., Tercier, S. et al. Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells. Oncogene 31, 48–59 (2012). https://doi.org/10.1038/onc.2011.218
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.218
Keywords
This article is cited by
-
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target
Molecular Cancer (2022)
-
Targeting PDZ domains as potential treatment for viral infections, neurodegeneration and cancer
Biology Direct (2021)
-
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis
Scientific Reports (2021)
-
MAGI1 mediates tumor metastasis through c-Myb/miR-520h/MAGI1 signaling pathway in renal cell carcinoma
Apoptosis (2019)
-
A genome scan for quantitative trait loci affecting average daily gain and Kleiber ratio in Baluchi Sheep
Journal of Genetics (2018)